|
|
Pipeline Insight: Prostate Cancer - Domination By The Innovative ClassesPublished by: Datamonitor Published: May. 16, 2003 - 234 Pages Table of ContentsCHAPTER 1 EXECUTIVE SUMMARY Scope of the analysis Datamonitor insight into the prostate cancer market Summary Key metrics CHAPTER 2 PATIENT POTENTIAL Definition of prostate cancer Diagnosis of disease Treatment Classification of prostate cancer Staging Stage I Stage II Stage III Stage IV Gleason Score Gleason grade 1 and 2 Gleason grade 3 Gleason grade 4 and 5 Segmentation of prostate cancer Hormone Refractory Prostate Cancer (HRPC) Second-line patient treatment Risk Epidemiology of prostate cancer Compliance rates Unmet need in prostate cancer CHAPTER 3 R&D APPROACH Classification of pipeline products Anti-hormonals LHRH agonists Anti-androgens Cytotoxics Innovatives Clinical trial design in prostate cancer Clinical trials for old versus new agents Clinical trial duration Patient selection Adjuvant trials Comparator drugs Earlier stages of clinical trial design Other hot issues in clinical trial design Clinical trial endpoints in prostate cancer Survival Quality of Life Disease-free survival Time to tumor progression Tumor Response Prostate specific antigen (PSA) Testosterone suppression to castrate levels CHAPTER 4 PROSTATE CANCER PIPELINE ANALYSIS Pipeline overview Key companies involved in the prostate cancer pipeline ABBOTT IN PROSTATE CANCER Keeping to products the company markets well Need for better strategic penetration Abbott’s position, 2001-2007 Abbott’s position 2003, increased emphasis on the cancer portfolio - future revenues are relying heavily on the success of Atrasentan AstraZeneca in prostate cancer and other hormonal cancers Top heavy portfolio - is there a need for balance? Strategies for success Takeda and TAP Pharmaceuticals Flexibility of TAP Pharmaceuticals Future of TAP - is the joint venture still fruitful CHAPTER 5 ANTI-HORMONALS LATE-STAGE DRUG ANALYSIS & FORECASTS Overview for Anti-hormonals Pipeline summary Definition of current comparator therapy CyPat88 Drug overview Clinical trial data Patient potential Marketing factors Satisfaction of unmet needs Forecasts to 2011 Quality of life of patients Launch of generic leuprolide and generic goserelin Increasing presence of Casodex Histrelin Hydrogel Implant Drug overview Clinical trial data Patient potential Marketing factors Satisfaction of unmet needs Forecasts to 2011 Agreement with Paladin - a possible lifeline for HMS Increasing competition from Viadur and launch of generic leuprolide and generic goserelin - a major threat Plenaxis Clinical trial data Patient potential Marketing factors Satisfaction of unmet needs Forecasts to 2011 Niche patient potential Generic leuprolide and generic goserelin Safety issues and delay of approval Comparison of key compounds in the anti-hormonals class Efficacy (HRPC) Side effect Efficacy (HSPC) Marketing strength Opinion leader thoughts Comparative forecasts CHAPTER 6 CYTOTOXICS LATE-STAGE DRUG ANALYSIS AND FORECASTS Overview for Cytotoxics Definition of current comparator therapy LED 117 Clinical trial data Patient potential Marketing factors Satisfaction of unmet needs Forecasts to 2011 Marketing power HRPC patient population Satraplatin Clinical trial data Patient potential Marketing potential Satisfaction of unmet needs Forecasts to 2011 Oral availability - a sure plus Taxotere - a major threat Other Late-stage development compounds Taxol Clinical trial data Satisfaction of unmet needs Forecasts to 2011 Off-label use Generic paclitaxel Taxotere Clinical trial data Satisfaction of unmet needs Forecasts to 2011 Off-label use - key to the drugs high first year sales Launch of innovatives Comparison of key compounds in the cytotoxics class Efficacy (HRPC) Side effect Marketing strength Opinion leader thoughts Comparative Forecasts CHAPTER 7 INNOVATIVES LATE-STAGE AND FORECASTS Overview for Innovatives Definition of current comparator therapy DN-101 149 Clinical trial data Patient potential Marketing potential Satisfaction of unmet needs Forecasts to 2011 Taxotere - a synergistic possibility Launch of Genasense Atrasentan Clinical trial data Patient potential Marketing potential Satisfaction of unmet needs Forecasts to 2011 US and European launch Safety profile Thalomid Clinical trial data Patient potential Marketing potential Satisfaction of unmet needs Forecasts to 2011 Marketing campaign - bring in S.T.E.P.S Widely recognized - good or bad? More IMIDS to follow Provenge Clinical trial data Patient potential Marketing potential Satisfaction of unmet needs Forecasts to 2011 Patient niche population Lack of long-term patient cohorts - growth inhibition likely Cost of treatment & laboratory usage LDI-200 185 Comparison of key compounds in the cytotoxics class Efficacy (HRPC) Side effect Marketing strength Opinion leader thoughts Other Late-stage development compounds GVAX Forecasts to 2011 Competition with other immunotherapies - the biggest challenge will be to differentiate Onyvax -P Forecasts to 2011 Competition with competitors Genasense Forecasts to 2011 Aventis and Genta - strong combination Comparative Forecasts CHAPTER 8 INNOVATIVE EARLY-STAGE PROJECTS Key phase I and preclinical compounds in prostate cancer Advexin (INGN-201) Advantages and disadvantages of cancer gene therapy Velcade (bortezomib) Avicine (beta-hCG oligonucleotides) Forging an alliance to optimize revenue potential The market potential of AVI’s therapeutic vaccine Key research impacts on prostate cancer Preventative drugs for prostate cancer Proscar (finasteride) Selenium Vitamin E APPENDIX A Contributing experts List of tables List of figures Bibliography Key companies involved in the prostate cancer pipeline Forecasting methodology Predicting first year market share Clinical competitiveness attributes Market strategy attributes Company profile attributes Drug class growth Individual drug growth Influencing factors Influencing factors Increased prevalence Launch of new drug classes Expansion of existing drug classes Increased use of combination therapies Increased diagnosis Patent expiry and genericization Cost containment MediCare reformation Disease management APPENDIX B About Datamonitor About Datamonitor Healthcare Datamonitor Healthcare’s research and analysis methodologies Datamonitor Healthcare’s therapy area capabilities About Disease analysis team Datamonitor Healthcare’s Consulting expertise Datamonitor’s Therapeutic Consulting expertise Key therapy team members Simon Hemsworth, Director of Therapy Area Analysis Fil Manuguid, Global Oncology Business Director Kate Bradley, Managing Analyst Oncology Sharon Arkoff, Global Oncology Editor Disclaimer AbstractIntroduction:Prostate cancer, the most prevalent cancer for men, is a very large and very competitive market. The anti-androgen and LHRH analog drug classes currently dominate the market. With the development of a number of innovative therapies from new pharmaceutical companies entering the market for the first time, the prostate cancer market is about to enter a more dynamic and high growth phase. Scope: * Analysis of late-stage pipelines: anti-hormonals, cytotoxics, and innovatives, with sales forecasts to 2011; plus overview of early-stage innovatives * Patient potential, highlighting trends in incidence, prevalence and diagnosis of prostate cancer * Analysis of the global prostate cancer market, identifying key market and treatment trends * Case studies featuring the leading global players: AstraZeneca, Abbott and TAP Pharmaceuticals Report Highlights: Innovative drugs have made their mark in the prostate cancer pipeline but this does not guarantee good uptake among physicians More drugs are in development for the greatest unmet need in prostate cancer Prevalence of prostate cancer at over 2m in 2003 in the seven major markets Reasons to Purchase: * Characterize saturated and under-served markets in Prostate Cancer. Are the anti-hormonals still an attractive class? * Identify the key unmet needs in Prostate Cancer - will the innovatives group satisfy them? * Find potential out-licensing and co-marketing partners in the Prostate Cancer market Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||